Seres Therapeutics (MCRB) Misses Q3 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
November 8, 2018 7:00 AM EST- Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer -
- Planning for two new microbiome clinical studies in ulcerative colitis and metastatic melanoma; Company expects to receive $40M in payments from Nestlé Health Science with SER-287 Phase 2b study start -
- Conference call at 8:30 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
